InvestorsHub Logo
Followers 10
Posts 4220
Boards Moderated 0
Alias Born 07/10/2003

Re: chiggah post# 72769

Thursday, 11/15/2007 3:58:20 PM

Thursday, November 15, 2007 3:58:20 PM

Post# of 82595
Some very good questions, some of the answers are obvious, some are a little less so.

What improvements have we made to our forensic products that make them more valid and sellable?

In order to make a product more viable and saleable to the market, improvements have to be made public. It does no good to make significant improvements to increase sales and then not tell anyone anyone about the improvements. If your market is unaware of the improvements there can be no benefit. Furthermore, DNAG never misses an opportunity to announce even the slightest news with a PR. Since we have heard nothing, it is a safe bet that no marketable improvements have been made.

When we hook up with a bonafide company such as Beckman-Coulter, how will that improve our overall standing in the market place when other big companies need SNP work done?

Beckman-Coulter makes money by selling the recurring supplies to those making use of their machines, much like HP makes money from the ink cartridges used in their printers. Just like HP doesn't care what someone prints as long as they buy the ink, Beckman-Coulter would make money if DNAG was selling tests to determine Martian' ancestry. The point is that there is no inherent validation contained in such a one sided 'collaboration'.

Does anybody realize that with these last two agreements, DNAPrint will have a plethora of genome data samples to continue it's overall research?

Yes, and no. These tests (for both BioServe and the forensic tests distributed by Beckman) are already established tests. They only look at a very few specific markers. The results will be confined to the existence or lack thereof of those markers. There will be no other data. The data sets that DNAG needs for it's further research are much more extensive, requiring population sorted my characteristics. Ovanome, for example, requires data sets from women with ovarian cancer sorted into two groups those reacting positively to their treatment and those reacting negatively. With those data sets they can further their research. All the rest of their programs require equivalent 'sorted' data sets.

In summary, good questions.........easy answers.

regards,
frog